Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

The article identifies Vertex Pharmaceuticals (VRTX), Iovance Therapeutics (IOVA), and Summit Therapeutics (SMMT) as potentially high-performing healthcare stocks through 2030, citing their innovative drug pipelines and market positioning. Vertex is expected to grow with its non-opioid pain treatment Journavx and potential approvals for povetacicept and zimislecel, despite some challenges with copycat drugs in Russia. Iovance, with its approved Amtagvi T-cell therapy for melanoma, is expanding into other cancers, while Summit anticipates success with ivonescimab, an immunotherapy licensed from Akeso, showing promise in NSCLC treatment, with key clinical trial results expected in mid-2025.

Analysis

The healthcare sector is presented as offering resilient growth, driven by consistent demand and aging populations, with a focus on three drugmakers—Vertex Pharmaceuticals (VRTX), Iovance Therapeutics (IOVA), and Summit Therapeutics (SMMT)—as potential high-performers through 2030. Vertex Pharmaceuticals, despite lower-than-expected Q1 results due to illegal drug sales in Russia and a temporary pause in a Phase 1/2 study for VX-522, is highlighted for its strong cystic fibrosis franchise and significant growth potential from new products. Notably, Journavx, a non-opioid treatment for acute pain, recently received FDA approval and is expected to see rapid sales growth. Vertex also anticipates filing for accelerated approval of povetacicept for IgA nephropathy in H1 2026 and for FDA approval of zimislecel for severe type 1 diabetes next year. Iovance Therapeutics has its first FDA-approved T-cell therapy for a solid tumor, Amtagvi, for advanced melanoma, and is pursuing label expansions into cervical cancer, endometrial cancer, head and neck squamous cell carcinoma, and non-small-cell lung cancer (NSCLC), including combination trials with products from Merck and Bristol Myers Squibb. However, Iovance experienced lower-than-expected Q1 sales for Amtagvi due to facility maintenance, underscoring challenges in launching complex therapies. Summit Therapeutics, currently without an approved product, holds promise with ivonescimab, an immunotherapy licensed from Akeso, which has shown superiority over Keytruda and Tevimbra in non-US NSCLC studies. Summit expects top-line results from its Harmoni study for ivonescimab in mid-2025 and is also exploring its use in other cancers through collaborations with MD Anderson and Pfizer. The overall sentiment towards these prospects is positive (0.7), with VRTX (0.6), SMMT (0.5), and IOVA (0.4) reflecting this optimism.

Key Decisions for Investors

• Investors should closely monitor the commercial uptake of Vertex's Journavx and the progression of its pipeline candidates povetacicept and zimislecel through clinical trials and regulatory submissions, balancing these growth drivers against existing franchise risks.
• For Iovance Therapeutics, focus should be on Amtagvi's sales trajectory post-Q1 challenges and the clinical development progress in new indications, recognizing the execution risks associated with complex T-cell therapies.
• Summit Therapeutics presents a catalyst-driven opportunity heavily dependent on the mid-2025 Harmoni study results for ivonescimab; investors should weigh the potential upside against the inherent risks of a company awaiting its first product approval.
• Consider the specific clinical and regulatory milestones for each company as key inflection points for potential re-evaluation of positions, given the high-risk, high-reward nature of developmental-stage biotech investments within a generally favorable sector outlook.